These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39011565)

  • 1. Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review.
    Okano SHP; Braga GC; Cantelli DAL; Filho LASP; Brito LGO; Lara LADS
    Andrology; 2024 Jul; ():. PubMed ID: 39011565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years.
    Madsen MC; van Dijk D; Wiepjes CM; Conemans EB; Thijs A; den Heijer M
    J Clin Endocrinol Metab; 2021 May; 106(6):1710-1717. PubMed ID: 33599731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence.
    Defreyne J; Vantomme B; Van Caenegem E; Wierckx K; De Blok CJM; Klaver M; Nota NM; Van Dijk D; Wiepjes CM; Den Heijer M; T'Sjoen G
    Andrology; 2018 May; 6(3):446-454. PubMed ID: 29602229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythrocytosis in Gender-Affirming Care With Testosterone.
    Porat AT; Ellwood M; Rodina M; Dianat S
    Ann Fam Med; 2023; 21(5):403-407. PubMed ID: 37748907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone.
    Oakes M; Arastu A; Kato C; Somers J; Holly HD; Elstrott BK; Dy GW; Kohs TCL; Patel RR; McCarty OJT; DeLoughery TG; Milano C; Raghunathan V; Shatzel JJ
    Thromb Res; 2021 Nov; 207():96-98. PubMed ID: 34592628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythrocytosis Is Rare With Exogenous Testosterone in Gender-Affirming Hormone Therapy.
    Krishnamurthy N; Slack DJ; Kyweluk M; Cullen O; Kirkley J; Safer JD
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1285-1290. PubMed ID: 38011684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of erythrocytosis in transgender individuals undergoing testosterone therapy: a systematic review.
    Scala A; Graziani A; Vianello F; Ferlin A; Garolla A;
    Minerva Endocrinol (Torino); 2024 Jun; 49(2):205-216. PubMed ID: 39028210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male.
    Jones SD; Dukovac T; Sangkum P; Yafi FA; Hellstrom WJ
    Sex Med Rev; 2015 Apr; 3(2):101-112. PubMed ID: 27784544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review.
    Velho I; Fighera TM; Ziegelmann PK; Spritzer PM
    Andrology; 2017 Sep; 5(5):881-888. PubMed ID: 28709177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis.
    Aghazadeh M; Pastuszak AW; Johnson WG; McIntyre MG; Hsieh TM; Lipshultz LI
    J Urol; 2015 Jul; 194(1):160-5. PubMed ID: 25596360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen.
    Pastuszak AW; Gomez LP; Scovell JM; Khera M; Lamb DJ; Lipshultz LI
    Sex Med; 2015 Sep; 3(3):165-73. PubMed ID: 26468380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SERUM HORMONE CONCENTRATIONS IN TRANSGENDER INDIVIDUALS RECEIVING GENDER-AFFIRMING HORMONE THERAPY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY.
    Chantrapanichkul P; Stevenson MO; Suppakitjanusant P; Goodman M; Tangpricha V
    Endocr Pract; 2021 Jan; 27(1):27-33. PubMed ID: 33471729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Changes in Hematologic Parameters Among Transgender People Receiving Hormone Therapy.
    Antun A; Zhang Q; Bhasin S; Bradlyn A; Flanders WD; Getahun D; Lash TL; Nash R; Roblin D; Silverberg MJ; Tangpricha V; Vupputuri S; Goodman M
    J Endocr Soc; 2020 Nov; 4(11):bvaa119. PubMed ID: 33834151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of secondary erythrocytosis in men receiving testosterone therapy A matched-cohort analysis of intranasal gel, injections, and pellets.
    Reddy R; Diaz P; Blachman-Braun R; Loloi J; Rahman F; Ory J; Dullea A; Zucker I; Gonzalez DC; Kresch E; Ramasamy R
    Can Urol Assoc J; 2023 Jul; 17(7):E202-E207. PubMed ID: 37068153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trans men can achieve adequate muscular development through low-dose testosterone therapy: A long-term study on body composition changes.
    Tominaga Y; Kobayashi T; Matsumoto Y; Moriwake T; Oshima Y; Okumura M; Horii S; Sadahira T; Katayama S; Iwata T; Nishimura S; Bekku K; Edamura K; Sugimoto M; Kobayashi Y; Watanabe M; Namba Y; Matsumoto Y; Nakatsuka M; Araki M
    Andrology; 2024 Apr; ():. PubMed ID: 38563871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of testosterone therapy on constructs related to aggression in transgender men: A systematic review.
    Kristensen TT; Christensen LL; Frystyk J; Glintborg D; T'Sjoen G; Roessler KK; Andersen MS
    Horm Behav; 2021 Feb; 128():104912. PubMed ID: 33309817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythrocytosis Following Testosterone Therapy.
    Ohlander SJ; Varghese B; Pastuszak AW
    Sex Med Rev; 2018 Jan; 6(1):77-85. PubMed ID: 28526632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription Patterns and Testosterone Concentrations Achieved With AndroForte 5% Testosterone Cream in Transgender and Gender Diverse Individuals.
    Nolan BJ; Zwickl S; Locke P; Simpson S; Li L; Zajac JD; Cheung AS
    J Sex Med; 2022 Jun; 19(6):1049-1054. PubMed ID: 35365401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 12 Months' Treatment with Testosterone Undecanoate on Markers for Erythropoietic Activity and Safety Aspects in Transgender and Cisgender Hypogonadal Men.
    Lethin K; Aardal E; Lood Y; Ekman B; Wahlberg J
    J Appl Lab Med; 2024 Mar; 9(2):223-236. PubMed ID: 38085088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.